NCT07868081Not yet recruiting
A Study to Better Understand the Diagnosis and Treatment of Polycythaemia Vera
Knowledge, Attitudes and Practices Through Unified Real-world Experimental Vignettes in Polycythemia Vera (PV): KAPTURE-PV, a Multi-Country Vignette-Based Observational Study
Source: ClinicalTrials.gov · Last updated 9 Oct 2026
Brief summary (registry, in English)
PV is a rare, long-term blood cancer that causes the body to make too many blood cells. This can make the blood thicker than normal and the risk of blood clots higher. People with PV often experience symptoms that can affect their daily lives. Understanding how doctors diagnose and treat PV in everyday medical practice in a certain country can help find the differences in knowledge, diagnosis, and treatment of PV across countries. This study will not review or collect data from actual people with PV. It will collect information on the diagnosis and treatment of PV using a standard set of questions on and examples of fictional (unreal) people with PV. This is called clinical vignette. The study will ask doctors from several countries to complete this survey. The main aim of this study is to better understand how well doctors know about and diagnose PV and how they treat PV in certain countries. Other aims are to better understand how PV is managed and treated in everyday medical practice across countries. This includes which treatment people with PV receive once they are diagnosed and how access to medicines and healthcare services and other factors affects a doctor's treatment decisions for PV.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 90 (estimated)
- First submitted
- 5 Oct 2026
- Start date
- Dec 2026
- Primary completion date
- Mar 2027
- Lead sponsor
- Takeda
- Diseases
- Myeloproliferative neoplasms
- NCT number
- NCT07868081
What you commit to
- Study type: Observational
- Planned participants: 90
- From Dec 2026 to the primary completion date, Mar 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Physicians not currently involved in the diagnosis or management of PV patients.
- Medical trainees, residents, or fellows not yet board-certified or independently practicing.
- Practicing outside of KSA or Ukraine or Türkiye.
- Unwilling or unable to provide informed consent or complete the study procedures.
Who the study is looking for
- Board-certified or practicing hematology specialists actively managing PV patients.
- Currently practicing in a hospital or clinic setting in the Kingdom of Saudi Arabia or Ukraine or Türkiye.
- Minimum of 3 years of experience in the management of myeloproliferative neoplasms and/or hematological malignancies. Actively managing a minimum number of PV patients, defined as either:
- Has managed at least 10 patients with PV during the past 3 to 5 years, or at least 3 to 5 patients with PV during the past 12 months.
- Willing and able to provide informed consent and participate in a standardized survey and vignette assessment in a language in which the approved study materials are available, including English, Turkish, or Ukrainian, as applicable to the participating country.
Criteria the registry did not label
- This study is based on physician responses to standardized clinical vignettes. Therefore, eligibility applies to participating physicians:
Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.